HAMP and age-related macular degeneration: Although clinical trials of hepcidin agonists or mimetics in AMD have not yet been reported, therapeutic modulation of hepcidin signaling—or mimicking its iron-restrictive effects—represents a novel strategy to reduce retinal free iron, mitigate iron-driven ROS formation and lipid peroxidation, and inhibit ferroptosis.